Charlesson is an Oklahoma-based pharmaceutical company located in the Presbyterian Health Foundation’s Research Park. Charlesson is actively engaged in the development of therapeutics for treating debilitating ophthalmic diseases. Our product pipeline includes pharmaceutical treatments for Age-Related Macular Degeneration, Diabetic Retinopathy, Ocular Inflammation, Angiogenesis, and systemic diabetes.
Charlesson’s lead candidate, CLT-005, is for the treatment of Wet AMD, for which there is no therapeutic currently approved.
In addition to drug development, Charlesson also offers preclinical contract research with unique capabilities for ophthalmic testing such as:
- Angiogenesis Models
- Diabetic Models
- Macular Degeneration Models
- Retinal Degeneration Models
- in-vitro Studies
- Various Assays